Detalhe da pesquisa
1.
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.
Am J Hematol
; 98(12): 1856-1868, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37772428
2.
Matrix metalloproteinase-9 induces a pro-angiogenic profile in chronic lymphocytic leukemia cells.
Biochem Biophys Res Commun
; 520(1): 198-204, 2019 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31585732
3.
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
Haematologica
; 104(11): 2249-2257, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30890600
4.
A catalytically inactive gelatinase B/MMP-9 mutant impairs homing of chronic lymphocytic leukemia cells by altering migration regulatory pathways.
Biochem Biophys Res Commun
; 495(1): 124-130, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29080742
5.
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia.
Br J Haematol
; 176(4): 618-628, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27977057
6.
PLCG1 mutations in cutaneous T-cell lymphomas.
Blood
; 123(13): 2034-43, 2014 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-24497536
7.
A novel CD44-binding peptide from the pro-matrix metalloproteinase-9 hemopexin domain impairs adhesion and migration of chronic lymphocytic leukemia (CLL) cells.
J Biol Chem
; 289(22): 15340-9, 2014 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-24739387
8.
Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
Br J Haematol
; 169(2): 188-98, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25521006
9.
Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways.
Biochem Biophys Res Commun
; 461(2): 243-8, 2015 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-25869069
10.
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
Blood
; 122(24): 3951-9, 2013 Dec 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-24124086
11.
Haplo-cord transplantation using CD34+ cells from a third-party donor to speed engraftment in high-risk patients with hematologic disorders.
Biol Blood Marrow Transplant
; 20(12): 2015-22, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25255162
12.
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.
Haematologica
; 99(3): 505-10, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24162789
13.
Comparative Review of the Current and Future Strategies to Evaluate Bone Marrow Infiltration at Diffuse Large B-Cell Lymphoma Diagnosis.
Diagnostics (Basel)
; 14(6)2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38535078
14.
A 17-residue sequence from the matrix metalloproteinase-9 (MMP-9) hemopexin domain binds α4ß1 integrin and inhibits MMP-9-induced functions in chronic lymphocytic leukemia B cells.
J Biol Chem
; 287(33): 27601-13, 2012 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-22730324
15.
Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study.
Leuk Lymphoma
; 64(5): 913-926, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37255002
16.
VEGF/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration.
Blood
; 115(4): 846-9, 2010 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-19965686
17.
A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results.
Leuk Lymphoma
; 63(1): 93-100, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34459702
18.
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.
J Hematol Oncol
; 15(1): 116, 2022 08 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36028857
19.
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
J Clin Oncol
; 39(31): 3441-3452, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34310172
20.
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).
PLoS One
; 16(9): e0257353, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34506616